×
About 540 results

ALLMedicine™ Desmoid Tumor Center

Research & Reviews  183 results

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
https://clinicaltrials.gov/ct2/show/NCT05490667

Aug 8th, 2022 - Thirty patients with desmoid tumor (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital. This is a prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of anl...

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT04195399

Aug 4th, 2022 - PRIMARY OBJECTIVES: I. To estimate the 2-year progression-free survival (PFS) rate in patients with progressive, surgically unresectable desmoid tumor treated with nirogacestat. II. To describe the toxicities of nirogacestat in children and adoles...

Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review a...
https://doi.org/10.1007/s10238-022-00849-6
Clinical and Experimental Medicine; Prete F, Rotelli M et. al.

Aug 2nd, 2022 - Sporadic intra-abdominal desmoid tumors are rare and known to potentially occur after trauma including previous surgery, although knowledge of the underlying pathogenetic mechanism is still limited. We reviewed the recent literature on sporadic in...

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
https://clinicaltrials.gov/ct2/show/NCT02961374

Jul 26th, 2022 - PRIMARY OBJECTIVES: I. To assess the mean percent change in duodenal polyp burden (sum of diameters from all polyps) from baseline to 6 months post-intervention for familial adenomatous polyposis (FAP) subjects receiving weekly erlotinib hydrochlo...

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
https://clinicaltrials.gov/ct2/show/NCT03785964

Jul 21st, 2022 - Desmoid tumors, also referred to as aggressive fibromatosis, are rare, locally invasive, slow growing soft tissue tumors. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and occa...

see more →

Clinicaltrials.gov  21 results

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
https://clinicaltrials.gov/ct2/show/NCT05490667

Aug 8th, 2022 - Thirty patients with desmoid tumor (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital. This is a prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of anl...

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT04195399

Aug 4th, 2022 - PRIMARY OBJECTIVES: I. To estimate the 2-year progression-free survival (PFS) rate in patients with progressive, surgically unresectable desmoid tumor treated with nirogacestat. II. To describe the toxicities of nirogacestat in children and adoles...

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
https://clinicaltrials.gov/ct2/show/NCT02961374

Jul 26th, 2022 - PRIMARY OBJECTIVES: I. To assess the mean percent change in duodenal polyp burden (sum of diameters from all polyps) from baseline to 6 months post-intervention for familial adenomatous polyposis (FAP) subjects receiving weekly erlotinib hydrochlo...

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
https://clinicaltrials.gov/ct2/show/NCT03785964

Jul 21st, 2022 - Desmoid tumors, also referred to as aggressive fibromatosis, are rare, locally invasive, slow growing soft tissue tumors. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and occa...

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
https://clinicaltrials.gov/ct2/show/NCT01265030

Jul 7th, 2022 - We propose a translational research project that will directly test the hypothesis that mTOR is active in desmoid tumor in children and young adults. Activity will be assessed by clinical and histological studies following a course of pre-operativ...

see more →

News  9 results

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors
https://www.onclive.com/view/dr-d-amato-on-optimizing-treatment-for-patients-with-desmoid-tumors

Dec 21st, 2021 - Gina Z. D’Amato, MD, associate professor, assistant director of clinical research, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses optimizing treatment for patients with desmoid tumors. ...

Observation May Be Preferrable to Surgery in Certain Cases of Desmoid Tumor Fibromatosis
https://www.onclive.com/view/observation-may-be-preferrable-to-surgery-in-certain-cases-of-desmoid-tumor-fibromatosis

Apr 29th, 2021 - The local recurrence rate after surgical excision was similar to the rate of progression with active surveillance in patients with extra-abdominal desmoid tumor fibromatosis (DTF), suggesting that observation may be sufficient in some cases of DTF...

Randall Underscores the Need for Multidisciplinary Management of Desmoid Fibromatosis
https://www.onclive.com/view/randall-underscores-the-need-for-multidisciplinary-management-of-desmoid-fibromatosis

Aug 22nd, 2020 - Desmoid fibromatosis is a rare soft tissue neoplasm that can often be as severe as sarcoma in terms of the problems it can create, according to R. Lor Randall, MD, FACS, who added that in order to manage this disease appropriately, each case shoul...

Progress in Rare Cancers Is ASCO Advance of the Year
https://www.medscape.com/viewarticle/908643

Feb 4th, 2019 - Advances in the treatment of rare cancers have been chosen as the clinical cancer advances of the year by the American Society of Clinical Oncology (ASCO). ASCO's annual report on progress against cancer, issued for the 14th consecutive year, was ...

Sorafenib extends PFS for refractory desmoid tumors
https://www.mdedge.com/sarcomajournal/article/191511/sarcoma/sorafenib-extends-pfs-refractory-desmoid-tumors
Neil Osterweil

Dec 19th, 2018 - For patients with progressive, refractory, or symptomatic desmoid tumors – also known as aggressive fibromatosis – treatment with daily sorafenib (Nexavar) was associated with durable responses and a significant improvement in progression-free sur.

see more →

Patient Education  3 results see all →